In SURMOUNT-1, people taking 15 mg of tirzepatide lost on average 22.5% of body weight -- representing a mean loss of 52 lb (24 kg) by week 72. And in STEP 1, people on semaglutide lost an average ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...

Higher doses of tirzepatide were particularly effective, with mean fasting insulin percent reductions of 27.76% (P =.003; 10 mg dose) and 37.0% (P <.00001; 15 mg dose) compared with placebo. All doses ...

After a median follow-up of two years and a maximum of three years, cardiovascular death or worsening heart failure events occurred in 9.9% of the tirzepatide group and 15.3% of those taking placebo.

Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...

Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, causes considerable weight loss. New research findings of its effect on ...

Medications like semaglutide and tirzepatide have gained significant attention for their impressive weight-loss effects, but they do much more than just helping you shed pounds. Let’s dive into ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...